Is BDSX or OPK more profitable?

OPKO Health has a net margin of -12.40% compared to Biodesix's net margin of -26.97%. OPKO Health's return on equity of -5.88% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% OPKO Health -12.40% -5.88% -3.83%

Does the media refer more to BDSX or OPK?

In the previous week, Biodesix had 1 more articles in the media than OPKO Health. MarketBeat recorded 6 mentions for Biodesix and 5 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.80 beat Biodesix's score of 0.38 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OPKO Health 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, INNV or BDSX?

InnovAge has higher revenue and earnings than Biodesix. InnovAge is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InnovAge $989.71M 1.24 -$2.54M -$0.02 N/A Biodesix $88.50M 3.30 -$35.26M -$3.17 N/A

Is INNV or BDSX more profitable?

InnovAge has a net margin of -0.26% compared to Biodesix's net margin of -26.97%. InnovAge's return on equity of -1.03% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets InnovAge -0.26% -1.03% -0.47% Biodesix -26.97% -788.19% -30.33%

Does the media prefer INNV or BDSX?

In the previous week, InnovAge had 6 more articles in the media than Biodesix. MarketBeat recorded 12 mentions for InnovAge and 6 mentions for Biodesix. InnovAge's average media sentiment score of 0.66 beat Biodesix's score of 0.38 indicating that InnovAge is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, BDSX or OMDA?

Omada Health has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Omada Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 3.30 -$35.26M -$3.17 N/A Omada Health $260.21M 4.79 -$12.78M $0.05 407.40

Is BDSX or OMDA more profitable?

Omada Health has a net margin of 1.39% compared to Biodesix's net margin of -26.97%. Omada Health's return on equity of 2.60% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% Omada Health 1.39% 2.60% 1.98%

Does the media favor BDSX or OMDA?

In the previous week, Biodesix had 2 more articles in the media than Omada Health. MarketBeat recorded 6 mentions for Biodesix and 4 mentions for Omada Health. Omada Health's average media sentiment score of 0.82 beat Biodesix's score of 0.38 indicating that Omada Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omada Health 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CSTL or BDSX?

In the previous week, Castle Biosciences had 5 more articles in the media than Biodesix. MarketBeat recorded 11 mentions for Castle Biosciences and 6 mentions for Biodesix. Castle Biosciences' average media sentiment score of 0.43 beat Biodesix's score of 0.38 indicating that Castle Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LMRI or BDSX?

In the previous week, Biodesix had 2 more articles in the media than Lumexa Imaging. MarketBeat recorded 6 mentions for Biodesix and 4 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.67 beat Biodesix's score of 0.38 indicating that Lumexa Imaging is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lumexa Imaging 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biodesix (BDSX) Competitors

$27.72 +0.39 (+1.43%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$27.77 +0.05 (+0.18%)

As of 10/2/2026 07:55 PM Eastern

Compare

BDSX vs. OPK, INNV, OMDA, CSTL, and LMRI

Should you buy Biodesix stock or one of its competitors? Biodesix's main competitors and comparable companies include OPKO Health (OPK), InnovAge (INNV), Omada Health (OMDA), Castle Biosciences (CSTL), and Lumexa Imaging (LMRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Biodesix compare to OPKO Health?

Biodesix (NASDAQ:BDSX) and OPKO Health (NASDAQ:OPK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Biodesix has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

OPKO Health has a net margin of -12.40% compared to Biodesix's net margin of -26.97%. OPKO Health's return on equity of -5.88% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
OPKO Health	-12.40%	-5.88%	-3.83%

Biodesix currently has a consensus price target of $35.00, suggesting a potential upside of 26.26%. OPKO Health has a consensus price target of $1.55, suggesting a potential downside of 0.64%. Given Biodesix's stronger consensus rating and higher probable upside, equities analysts clearly believe Biodesix is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
OPKO Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Biodesix had 1 more articles in the media than OPKO Health. MarketBeat recorded 6 mentions for Biodesix and 5 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.80 beat Biodesix's score of 0.38 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OPKO Health	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biodesix has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.30	-$35.26M	-$3.17	N/A
OPKO Health	$606.90M	1.92	-$225.68M	-$0.09	N/A

21.0% of Biodesix shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 44.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

OPKO Health beats Biodesix on 9 of the 16 factors compared between the two stocks.

How does Biodesix compare to InnovAge?

InnovAge (NASDAQ:INNV) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

In the previous week, InnovAge had 6 more articles in the media than Biodesix. MarketBeat recorded 12 mentions for InnovAge and 6 mentions for Biodesix. InnovAge's average media sentiment score of 0.66 beat Biodesix's score of 0.38 indicating that InnovAge is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.3% of InnovAge shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 1.0% of InnovAge shares are held by insiders. Comparatively, 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

InnovAge has higher revenue and earnings than Biodesix. InnovAge is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$989.71M	1.24	-$2.54M	-$0.02	N/A
Biodesix	$88.50M	3.30	-$35.26M	-$3.17	N/A

InnovAge has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

InnovAge has a net margin of -0.26% compared to Biodesix's net margin of -26.97%. InnovAge's return on equity of -1.03% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-0.26%	-1.03%	-0.47%
Biodesix	-26.97%	-788.19%	-30.33%

InnovAge currently has a consensus price target of $10.50, suggesting a potential upside of 17.19%. Biodesix has a consensus price target of $35.00, suggesting a potential upside of 26.26%. Given Biodesix's stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Biodesix beats InnovAge on 9 of the 17 factors compared between the two stocks.

How does Biodesix compare to Omada Health?

Biodesix (NASDAQ:BDSX) and Omada Health (NASDAQ:OMDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Omada Health has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Omada Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.30	-$35.26M	-$3.17	N/A
Omada Health	$260.21M	4.79	-$12.78M	$0.05	407.40

Biodesix has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Omada Health has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market.

Biodesix presently has a consensus price target of $35.00, indicating a potential upside of 26.26%. Omada Health has a consensus price target of $26.67, indicating a potential upside of 30.91%. Given Omada Health's higher possible upside, analysts clearly believe Omada Health is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Omada Health	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

21.0% of Biodesix shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 6.4% of Omada Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Omada Health has a net margin of 1.39% compared to Biodesix's net margin of -26.97%. Omada Health's return on equity of 2.60% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Omada Health	1.39%	2.60%	1.98%

In the previous week, Biodesix had 2 more articles in the media than Omada Health. MarketBeat recorded 6 mentions for Biodesix and 4 mentions for Omada Health. Omada Health's average media sentiment score of 0.82 beat Biodesix's score of 0.38 indicating that Omada Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omada Health	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omada Health beats Biodesix on 12 of the 17 factors compared between the two stocks.

How does Biodesix compare to Castle Biosciences?

Castle Biosciences (NASDAQ:CSTL) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Castle Biosciences had 5 more articles in the media than Biodesix. MarketBeat recorded 11 mentions for Castle Biosciences and 6 mentions for Biodesix. Castle Biosciences' average media sentiment score of 0.43 beat Biodesix's score of 0.38 indicating that Castle Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Castle Biosciences has higher revenue and earnings than Biodesix. Castle Biosciences is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	3.16	-$24.16M	-$0.66	N/A
Biodesix	$88.50M	3.30	-$35.26M	-$3.17	N/A

Castle Biosciences has a net margin of -5.43% compared to Biodesix's net margin of -26.97%. Castle Biosciences' return on equity of -4.15% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-5.43%	-4.15%	-3.45%
Biodesix	-26.97%	-788.19%	-30.33%

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Castle Biosciences has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Castle Biosciences presently has a consensus target price of $42.00, indicating a potential upside of 18.11%. Biodesix has a consensus target price of $35.00, indicating a potential upside of 26.26%. Given Biodesix's higher probable upside, analysts clearly believe Biodesix is more favorable than Castle Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Castle Biosciences beats Biodesix on 11 of the 15 factors compared between the two stocks.

How does Biodesix compare to Lumexa Imaging?

Lumexa Imaging (NASDAQ:LMRI) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

21.0% of Biodesix shares are owned by institutional investors. 0.7% of Lumexa Imaging shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biodesix has lower revenue, but higher earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lumexa Imaging	$267.73M	3.70	-$47.10M	-$0.49	N/A
Biodesix	$88.50M	3.30	-$35.26M	-$3.17	N/A

In the previous week, Biodesix had 2 more articles in the media than Lumexa Imaging. MarketBeat recorded 6 mentions for Biodesix and 4 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.67 beat Biodesix's score of 0.38 indicating that Lumexa Imaging is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lumexa Imaging	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lumexa Imaging has a net margin of 0.00% compared to Biodesix's net margin of -26.97%. Lumexa Imaging's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lumexa Imaging	N/A	N/A	N/A
Biodesix	-26.97%	-788.19%	-30.33%

Lumexa Imaging presently has a consensus price target of $16.00, indicating a potential upside of 55.04%. Biodesix has a consensus price target of $35.00, indicating a potential upside of 26.26%. Given Lumexa Imaging's stronger consensus rating and higher possible upside, equities research analysts plainly believe Lumexa Imaging is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Lumexa Imaging beats Biodesix on 10 of the 16 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDSX vs. The Competition

Export

Metric	Biodesix	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$292.47M	$9.59B	$7.14B	$13.17B
Dividend Yield	N/A	2.61%	2.53%	16.78%
P/E Ratio	-8.74	34.21	275.68	26.04
Price / Sales	2.84	5.39	662.25	102.14
Price / Cash	N/A	120.59	77.60	51.75
Price / Book	-89.42	5.15	10.93	6.31
Net Income	-$35.26M	$315.68M	$3.51B	$362.16M
7 Day Performance	-4.74%	-2.59%	-2.00%	-1.66%
1 Month Performance	4.68%	-3.19%	-6.15%	-4.50%
1 Year Performance	258.14%	7.93%	7.44%	2.06%

Biodesix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDSX Biodesix	4.1915 of 5 stars	$27.72 +1.4%	$35.00 +26.3%	+260.0%	$292.47M	$102.94M	N/A	334	News Coverage
OPK OPKO Health	1.2028 of 5 stars	$1.63 -0.3%	$1.55 -4.6%	+1.3%	$1.21B	$606.90M	N/A	1,373	News Coverage
INNV InnovAge	2.5504 of 5 stars	$8.76 -1.5%	$10.50 +19.9%	+79.9%	$1.19B	$989.71M	N/A	2,500	Insider Trade
OMDA Omada Health	3.6632 of 5 stars	$18.85 -2.8%	$26.67 +41.5%	-10.0%	$1.16B	$260.21M	378.10	946	Analyst Downgrade
CSTL Castle Biosciences	2.3843 of 5 stars	$34.46 -4.1%	$42.00 +21.9%	+60.0%	$1.05B	$344.23M	N/A	1,002	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDSX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodesix (BDSX) Competitors

BDSX vs. OPK, INNV, OMDA, CSTL, and LMRI

How does Biodesix compare to OPKO Health?

Summary

How does Biodesix compare to InnovAge?

Summary

How does Biodesix compare to Omada Health?

Summary

How does Biodesix compare to Castle Biosciences?

Summary

How does Biodesix compare to Lumexa Imaging?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodesix (BDSX) Competitors

BDSX vs. OPK, INNV, OMDA, CSTL, and LMRI

How does Biodesix compare to OPKO Health?

Which has more volatility and risk, BDSX or OPK?

Is BDSX or OPK more profitable?

Do analysts prefer BDSX or OPK?

Does the media refer more to BDSX or OPK?

Which has preferable valuation and earnings, BDSX or OPK?

Do insiders and institutionals hold more shares of BDSX or OPK?

Summary

How does Biodesix compare to InnovAge?

Does the media prefer INNV or BDSX?

Do institutionals & insiders hold more shares of INNV or BDSX?

Which has better valuation and earnings, INNV or BDSX?

Which has more risk and volatility, INNV or BDSX?

Is INNV or BDSX more profitable?

Do analysts prefer INNV or BDSX?

Summary

How does Biodesix compare to Omada Health?

Which has stronger earnings & valuation, BDSX or OMDA?

Which has more risk and volatility, BDSX or OMDA?

Do analysts recommend BDSX or OMDA?

Do insiders and institutionals believe in BDSX or OMDA?

Is BDSX or OMDA more profitable?

Does the media favor BDSX or OMDA?

Summary

How does Biodesix compare to Castle Biosciences?

Does the media refer more to CSTL or BDSX?

Which has stronger valuation and earnings, CSTL or BDSX?

Is CSTL or BDSX more profitable?

Do institutionals & insiders believe in CSTL or BDSX?

Which has more risk & volatility, CSTL or BDSX?

Do analysts rate CSTL or BDSX?

Summary

How does Biodesix compare to Lumexa Imaging?

Do insiders & institutionals hold more shares of LMRI or BDSX?

Which has preferable earnings & valuation, LMRI or BDSX?

Does the media prefer LMRI or BDSX?

Is LMRI or BDSX more profitable?

Do analysts prefer LMRI or BDSX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools